Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Stocks Climb on the Outlook for the Fed to Pause Rate Hikes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. U.S. stocks this morning are moderately higher, with the...

Barchart

Dow Jones Rallies As Oracle Pops On This; Elon Musk Mocks Short Call Amid Tesla Stock Surge

The Dow Jones rallied. Elon Musk mocked a prominent investor for shorting Tesla stock. Oracle earnings beat after it rose on an analyst call.

Investors Business Daily

Dow Jones Futures Rise: Bullish Market Breadth, But Fed Looms; Nvidia Has New Buy Point

A broader market rally is a reason to be bullish long term, but the Fed meeting is one reason to be cautious now. Biogen jumped late Friday. Watch Tesla and Nvidia.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Experimental Alzheimer's drug endorsed for full approval by FDA advisers

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

Axios

Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug

Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.

Investors Business Daily

Dow Jones Futures: Market Rally Turns Upside Down; Here's What To Do Now

Dow Jones futures: The market rally has routed out of the Nasdaq and into small- and mid-cap stocks. GameStop plunged late on news.

Investors Business Daily

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biogen Hits Buy Zone On A Fresh Win For Its Alzheimer's Treatment; Eli Lilly, Eisai Shares Jump

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Investors Business Daily

A Colorado panel of medical and pharmacy experts will decide whose medicine to make affordable this summer

Starting this summer, Colorado's Prescription Drug Affordability Board will choose up to 18 high-cost drugs for review.

Fortune

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Investors Business Daily

Eli Lilly Hits A Record-Smashing $409 Billion Market Cap Following Its Alzheimer's Win

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.

Investors Business Daily

Drug for rare form of Lou Gehrig’s disease OK'd by FDA

U.S. health regulators have approved a first-of-a-kind drug for a rare form of Lou Gehrig’s disease

The Independent UK

Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat

The FDA approved Biogen's new ALS drug on Tuesday, but Biogen stock remained hamstrung on a "low-quality earnings beat."

Investors Business Daily

Biogen Pops — But Ionis Hands Back Gains — After ALS Drug Wins A Key Endorsement

Biogen stock jumped — as Ionis stock gave back early gains — after a FDA panel offered a mixed view of their ALS treatment.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

The VA will pay for some to get new Alzheimer’s drug

The U.S. Veterans Health Administration will pay for some beneficiaries to get a new Alzheimer’s disease drug from Eisai Co. and Biogen Inc., positive news for a treatment that Eisai expects to bring in billions of dollar in sales in the next few years.

Investors Business Daily

Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed

Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.

Investors Business Daily

Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount

Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.

Investors Business Daily

Dow Jones Drops 200 Points On Strong Retail Sales; Tesla Reverses Lower Despite Buy Rating

The Dow Jones fell 200 points Wednesday on strong U.S. retail sales data. Tesla stock reversed lower even after a Barclays outperform rating.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures Fall After Market Rally Shrugs Off Hot Inflation, Tesla Races; Airbnb Flies On Earnings

The market rally held up despite hot inflation data. Boeing led new buys while Tesla ran higher. Airbnb soared late on earnings.

Chicago Tribune

Commentary: We shouldn’t get caught up in the hype over new Alzheimer’s drug

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Tribune News Service

Commentary: Too soon to celebrate new Alzheimer’s drug

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

Investors Business Daily

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.

The Conversation

What the FDA's accelerated approval of a new Alzheimer's drug could mean for those with the disease – 5 questions answered about lecanemab

The U.S. Food and Drug Administration approved the medication lecanemab, sold under the brand name Leqembi, on Jan. 6, 2023, through an “accelerated approval pathway” that fast-tracks promising clinical treatments for diseases in which there are no other currently effective options.

Asharq Al-Awsat

US Approves New Drug to Treat Alzheimer's Disease

The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease. The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized…

The Independent UK

Alzheimer’s drug that slows disease progression approved by FDA

U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.